<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Combinatorial Chemistry &amp; High Throughput Screening</journal-id><journal-title-group><journal-title xml:lang="en">Combinatorial Chemistry &amp; High Throughput Screening</journal-title><trans-title-group xml:lang="ru"><trans-title>Combinatorial Chemistry &amp; High Throughput Screening</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1386-2073</issn><issn publication-format="electronic">1875-5402</issn><publisher><publisher-name xml:lang="en">Bentham Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">644844</article-id><article-id pub-id-type="doi">10.2174/1386207326666230614102412</article-id><article-categories><subj-group subj-group-type="toc-heading"><subject>Chemistry</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Therapeutic Effect and Mechanism Prediction of Fuzi-Gancao Herb Couple on Non-alcoholic Fatty Liver Disease (NAFLD) based on Network Pharmacology and Molecular Docking</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Kejia</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Xu</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Guihong</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name><surname>Xiang</surname><given-names>Zheng</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff id="aff1"><institution>Graduate School, Liaoning University of Traditional Chinese Medicine</institution></aff><aff id="aff2"><institution>Department of Rehabilitation Medicine, General Hospital of Northern Theater Command</institution></aff><aff id="aff3"><institution>School of Pharmaceutical Science, Liaoning University</institution></aff><pub-date date-type="pub" iso-8601-date="2024-03-01" publication-format="electronic"><day>01</day><month>03</month><year>2024</year></pub-date><volume>27</volume><issue>5</issue><issue-title xml:lang="ru"/><fpage>773</fpage><lpage>785</lpage><history><date date-type="received" iso-8601-date="2025-01-07"><day>07</day><month>01</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Bentham Science Publishers</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Bentham Science Publishers</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://rjpbr.com/1386-2073/article/view/644844">https://rjpbr.com/1386-2073/article/view/644844</self-uri><abstract xml:lang="en"><p id="idm46041443783248">Background:Fuzi-Gancao herb couple is one of the most common herb couples involved in the TCM formula, which was used for the treatment of chronic diseases. The herb couple has a hepatoprotective effect. However, its main components and therapeutic mechanism are not yet clear. This study aims to elucidate the therapeutic effect and mechanism of the Fuzi-Gancao herb couple on NAFLD from animal experiments, network pharmacology, and molecular docking.</p><p id="idm46041443787248">Methods:60 Male C57BL/6 mice (20 g ± 2 g) were randomly divided into six groups including the blank group (n=10) and NALFD group (n=50). The mice of the NALFD group were fed with a high-fat diet for 20 weeks to establish the NAFLD model and the NALFD mice were randomly divided into five groups including positive group (berberine), model group and F-G groups with three dosages (0.257, 0.514, 0.771 g/kg) (n=10). After 10 weeks of administration, the serum was collected for the analysis of ALT, AST, LDL-c, HDL-c, and TC, and liver tissues were collected for pathological analysis. The TCMAS database was used to collect the main components and targets of the Fuzi-Gancao herb couple. The GeneCards database was used to collect NAFLD-related targets, and the key targets were obtained by intersecting with herbal targets. The diseasecomponent- target relationship diagram was constructed by Cytoscape 3.9.1. The obtained key targets were imported into the String database to obtain the PPI network, and imported into the DAVID database for KEGG pathway analysis and GO analysis. Finally, the key targets and key gene proteins were imported into Discovery Studio 2019 for molecular docking verification.</p><p id="idm46041443958464">Results:In this study, H-E staining indicated the pathological changes of liver tissue in Fuzi- Gancao groups were significantly improved, and the levels of AST, ALT, TC, HDL-c, and LDL-c in serum of Fuzi-Gancao groups decreased in a dose-dependent manner, compared with the model group. 103 active components and 299 targets in the Fuzi-Gancao herb couple were confirmed in the TCMSP database and 2062 disease targets in NAFLD were obtained. 142 key targets and 167 signal pathways were screened, such as the AGE-RAGE signaling pathway in diabetic complications, HIF-1 signaling pathway, IL-17 signaling pathway, TNF signaling pathway, and so on. The main bioactive ingredients of Fuzi-Gancao herb couple in the treatment of NAFLD are quercetin, kaempferol, naringenin, inermine, (R)-norcoclaurine, isorhamnetin, ignavine, 2,7-Dideacetyl-2,7- dibenzoyl-taxayunnanine F, glycyrol mainly involving IL6, AKT1, TNF, TP53, IL1B, VEGFA and other core targets. Molecular docking analysis indicated that there is a good affinity between the key components and the key targets.</p><p id="idm46041443793408">Conclusion:This study preliminarily explained the main components and mechanism of the Fuzi- Gancao herb couple in the treatment of NAFLD and provided an idea for subsequent research.</p></abstract><kwd-group xml:lang="en"><kwd>Fuzi-gancao herb couple</kwd><kwd>NAFLD</kwd><kwd>network pharmacology</kwd><kwd>molecular docking</kwd><kwd>AGE-RAGE</kwd><kwd>TNF.</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Loomba, R.; Friedman, S.L.; Shulman, G.I. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell, 2021, 184(10), 2537-2564. doi: 10.1016/j.cell.2021.04.015 PMID: 33989548</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Sanyal, A.J. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol., 2019, 16(6), 377-386. doi: 10.1038/s41575-019-0144-8 PMID: 31024089</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Lee, C.; Kim, J.; Jung, Y. Potential therapeutic application of estrogen in gender disparity of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Cells, 2019, 8(10), 1259. doi: 10.3390/cells8101259 PMID: 31619023</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Younossi, Z.M.; Golabi, P.; de Avila, L.; Paik, J.M.; Srishord, M.; Fukui, N.; Qiu, Y.; Burns, L.; Afendy, A.; Nader, F. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J. Hepatol., 2019, 71(4), 793-801. doi: 10.1016/j.jhep.2019.06.021 PMID: 31279902</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Noureddin, M.; Sanyal, A.J. Pathogenesis of NASH: The impact of multiple pathways. Curr. Hepatol. Rep., 2018, 17(4), 350-360. doi: 10.1007/s11901-018-0425-7 PMID: 31380156</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Ong, J.P.; Pitts, A.; Younossi, Z.M. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J. Hepatol., 2008, 49(4), 608-612. doi: 10.1016/j.jhep.2008.06.018 PMID: 18682312</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Pockros, P.J.; Fuchs, M.; Freilich, B.; Schiff, E.; Kohli, A.; Lawitz, E.J.; Hellstern, P.A.; Owens-Grillo, J.; Van Biene, C.; Shringarpure, R.; MacConell, L.; Shapiro, D.; Cohen, D.E. CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients. Liver Int., 2019, 39(11), 2082-2093. doi: 10.1111/liv.14209 PMID: 31402538</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Chan, W.K.; Wong, V.W.S. A new bile acid treatment for non-alcoholic fatty liver disease. Lancet Gastroenterol. Hepatol., 2019, 4(10), 747-749. doi: 10.1016/S2468-1253(19)30183-9 PMID: 31345779</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Cheung, A.; Figueredo, C.; Rinella, M.E. Nonalcoholic fatty liver disease: Identification and management of high-risk patients. Am. J. Gastroenterol., 2019, 114(4), 579-590. doi: 10.14309/ajg.0000000000000058 PMID: 30839326</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Chen, M.; Xie, Y.; Gong, S.; Wang, Y.; Yu, H.; Zhou, T.; Huang, F.; Guo, X.; Zhang, H.; Huang, R.; Han, Z.; Xing, Y.; Liu, Q.; Tong, G.; Zhou, H. Traditional Chinese medicine in the treatment of nonalcoholic steatohepatitis. Pharmacol. Res., 2021, 172, 105849. doi: 10.1016/j.phrs.2021.105849 PMID: 34450307</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Xu, Y.; Guo, W.; Zhang, C.; Chen, F.; Tan, H.Y.; Li, S.; Wang, N.; Feng, Y. Herbal medicine in the treatment of non-alcoholic fatty liver diseases-efficacy, action mechanism, and clinical application. Front. Pharmacol., 2020, 11, 601. doi: 10.3389/fphar.2020.00601 PMID: 32477116</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Keith, C.T.; Borisy, A.A.; Stockwell, B.R. Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discov., 2005, 4(1), 71-78. doi: 10.1038/nrd1609 PMID: 15688074</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Zhao, F.R.; Mao, H.P.; Zhang, H.; Hu, L.M.; Wang, H.; Wang, Y.F.; Yanagihara, N.; Gao, X.M. Antagonistic effects of two herbs in Zuojin Wan, a traditional Chinese medicine formula, on catecholamine secretion in bovine adrenal medullary cells. Phytomedicine, 2010, 17(8-9), 659-668. doi: 10.1016/j.phymed.2009.10.010 PMID: 20153155</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Wang, S.; Hu, Y.; Tan, W.; Wu, X.; Chen, R.; Cao, J.; Chen, M.; Wang, Y. Compatibility art of traditional Chinese medicine: From the perspective of herb pairs. J. Ethnopharmacol., 2012, 143(2), 412-423. doi: 10.1016/j.jep.2012.07.033 PMID: 22871585</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Shaw, L.H.; Lin, L.C.; Tsai, T.H. HPLC-MS/MS analysis of a traditional Chinese medical formulation of Bu-Yang-Huan-Wu-Tang and its pharmacokinetics after oral administration to rats. PLoS One, 2012, 7(8), e43848. doi: 10.1371/journal.pone.0043848 PMID: 22952787</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Middleton, J.; Md, E. Biological properties of plant flavonoids: An overview. Int. J. Pharmacogn., 1996, 34, 344-348. doi: 10.1076/phbi.34.5.344.13245</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Fu, X.; Lu, R.; Zhao, S. Simultaneous quantitation of six aconitum alkaloids and three flavonoids in the herb couple of radix aconiti lateralis-radix glycyrrhizae (FuziGancao) by UHPLC-ESI-MS/MS. Pharmacogn. Mag., 2017, 13(51), 425-429. doi: 10.4103/pm.pm_141_16 PMID: 28839367</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Wang, M.F.; Zhao, S.S.; Thapa, D.M.; Song, Y.L.; Xiang, Z. Metabolomics of Fuzi-Gancao in CCl4 induced acute liver injury and its regulatory effect on bile acid profile in rats. World J. Gastroenterol., 2021, 27(40), 6888-6907. doi: 10.3748/wjg.v27.i40.6888 PMID: 34790013</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Shin, J.H.; Jung, J.H. Non-alcoholic fatty liver disease and flavonoids: Current perspectives. Clin. Res. Hepatol. Gastroenterol., 2017, 41(1), 17-24. doi: 10.1016/j.clinre.2016.07.001 PMID: 27545758</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Song, R.; Qian, H.; Wang, Y.; Li, Q.; Li, D.; Chen, J.; Yang, J.; Zhong, J.; Yang, H.; Min, X.; Xu, H.; Yang, Y.; Chen, J. Research progress on the cardiovascular protective effect of glucagon-like peptide-1 receptor agonists. J. Diabetes Res., 2022, 2022, 1-8. doi: 10.1155/2022/4554996 PMID: 35434139</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Yang, H.; Yang, T.; Heng, C.; Zhou, Y.; Jiang, Z.; Qian, X.; Du, L.; Mao, S.; Yin, X.; Lu, Q. Quercetin improves nonalcoholic fatty liver by ameliorating inflammation, oxidative stress, and lipid metabolism in db/db mice. Phytother. Res., 2019, 33(12), 3140-3152. doi: 10.1002/ptr.6486 PMID: 31452288</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Porras, D.; Nistal, E.; Martínez-Flórez, S.; Pisonero-Vaquero, S.; Olcoz, J.L.; Jover, R.; González-Gallego, J.; García-Mediavilla, M.V.; Sánchez-Campos, S. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation. Free Radic. Biol. Med., 2017, 102, 188-202. doi: 10.1016/j.freeradbiomed.2016.11.037 PMID: 27890642</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Zhu, X.; Xiong, T.; Liu, P.; Guo, X.; Xiao, L.; Zhou, F.; Tang, Y.; Yao, P. Quercetin ameliorates HFD-induced NAFLD by promoting hepatic VLDL assembly and lipophagy via the IRE1a/XBP1s pathway. Food Chem. Toxicol., 2018, 114, 52-60. doi: 10.1016/j.fct.2018.02.019 PMID: 29438776</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Du, W.; An, Y.; He, X.; Zhang, D.; He, W. Protection of kaempferol on oxidative stress-induced retinal pigment epithelial cell damage. Oxid. Med. Cell. Longev., 2018, 2018, 1-14. doi: 10.1155/2018/1610751 PMID: 30584457</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Lee, B.; Kwon, M.; Choi, J.S.; Jeong, H.O.; Chung, H.Y.; Kim, H.R. Kaempferol isolated from Nelumbo nucifera inhibits lipid accumulation and increases fatty acid oxidation signaling in adipocytes. J. Med. Food, 2015, 18(12), 1363-1370. doi: 10.1089/jmf.2015.3457 PMID: 26280739</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Hoang, M.H.; Jia, Y.; Mok, B.; Jun, H.; Hwang, K.Y.; Lee, S.J. Kaempferol ameliorates symptoms of metabolic syndrome by regulating activities of liver X receptor-β. J. Nutr. Biochem., 2015, 26(8), 868-875. doi: 10.1016/j.jnutbio.2015.03.005 PMID: 25959373</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Jayachitra, J.; Nalini, N. Effect of naringenin (citrus flavanone) on lipid profile in ethanol‐induced toxicity in rats. J. Food Biochem., 2012, 36(4), 502-511. doi: 10.1111/j.1745-4514.2011.00561.x</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Zobeiri, M.; Belwal, T.; Parvizi, F.; Naseri, R.; Farzaei, M.H.; Nabavi, S.F.; Sureda, A.; Nabavi, S.M. Naringenin and its nano-formulations for fatty liver: cellular modes of action and clinical perspective. Curr. Pharm. Biotechnol., 2018, 19(3), 196-205. doi: 10.2174/1389201019666180514170122 PMID: 29766801</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Xie, X.; Yan, D.; Li, H.; Zhu, Q.; Li, J.; Fang, Y.P.; Cheung, C. W.; Irwin, M. G.; Xia, Z.; Lian, Q. Enhancement of adiponectin ameliorates nonalcoholic fatty liver disease via inhibition of FoxO1 in type I diabetic rats. J. Diabetes Res., 2018, 16(2018), 6254340. doi: 10.1155/2018/6254340</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Wu, H.; Chen, G.; Wang, J.; Deng, M.; Yuan, F.; Gong, J. TIM‐4 interference in Kupffer cells against CCL4‐induced liver fibrosis by mediating Akt1/Mitophagy signalling pathway. Cell Prolif., 2020, 53(1), e12731. doi: 10.1111/cpr.12731 PMID: 31755616</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Hendy, O.M.; Elsabaawy, M.M.; Aref, M.M.; Khalaf, F.M.; Oda, A.M.A.; El Shazly, H.M. Evaluation of circulating zonulin as a potential marker in the pathogenesis of nonalcoholic fatty liver disease. Acta Pathol. Microbiol. Scand. Suppl., 2017, 125(7), 607-613. doi: 10.1111/apm.12696 PMID: 28430371</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Kitade, H.; Chen, G.; Ni, Y.; Ota, T. Nonalcoholic fatty liver disease and insulin resistance: new insights and potential new treatments. Nutrients, 2017, 9(4), 387. doi: 10.3390/nu9040387 PMID: 28420094</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Braunersreuther, V.; Viviani, G.L.; Mach, F.; Montecucco, F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J. Gastroenterol., 2012, 18(8), 727-735. doi: 10.3748/wjg.v18.i8.727 PMID: 22371632</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Weijie, Z.; Hong, Z. Research advances in IL-6-mediated immunoinflammatory response and its relationship to disease. Cell. Mol. Immunol., 2017, 33, 699-703.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Wang, W.; Zhao, J.; Gui, W.; Sun, D.; Dai, H.; Xiao, L.; Chu, H.; Du, F.; Zhu, Q.; Schnabl, B.; Huang, K.; Yang, L.; Hou, X. Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease. Br. J. Pharmacol., 2018, 175(3), 469-484. doi: 10.1111/bph.14095 PMID: 29139555</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Yao, L.; Abe, M.; Kawasaki, K.; Akbar, S.M.F.; Matsuura, B.; Onji, M.; Hiasa, Y. Characterization of liver monocytic myeloid-derived suppressor cells and their role in a murine model of non-alcoholic fatty liver disease. PLoS One, 2016, 11(2), e0149948. doi: 10.1371/journal.pone.0149948 PMID: 26901500</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Yang, L.; Kwon, J.; Popov, Y.; Gajdos, G.B.; Ordog, T.; Brekken, R.A.; Mukhopadhyay, D.; Schuppan, D.; Bi, Y.; Simonetto, D. Vascular endothelial growth factor promotes fibrosis resolution and repair in mice. Gastroenterology, 2014, 146, 1339-1350.e1. doi: 10.1053/j.gastro.2014.01.061</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Patel, R.; Baker, S.S.; Liu, W.; Desai, S.; Alkhouri, R.; Kozielski, R.; Mastrandrea, L.; Sarfraz, A.; Cai, W.; Vlassara, H.; Patel, M.S.; Baker, R.D.; Zhu, L. Effect of dietary advanced glycation end products on mouse liver. PLoS One, 2012, 7(4), e35143. doi: 10.1371/journal.pone.0035143 PMID: 22496902</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Ott, C.; Jacobs, K.; Haucke, E.; Navarrete Santos, A.; Grune, T.; Simm, A. Role of advanced glycation end products in cellular signaling. Redox Biol., 2014, 2, 411-429. doi: 10.1016/j.redox.2013.12.016 PMID: 24624331</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Zeng, S.; Feirt, N.; Goldstein, M.; Guarrera, J.; Ippagunta, N.; Ekong, U.; Dun, H.; Lu, Y.; Qu, W.; Schmidt, A.M.; Emond, J.C. Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology, 2004, 39(2), 422-432. doi: 10.1002/hep.20045 PMID: 14767995</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Litwinoff, E.M.S.; Hurtado del Pozo, C.; Ramasamy, R.; Schmidt, A.M. Emerging targets for therapeutic development in diabetes and its complications: the RAGE signaling pathway. Clin. Pharmacol. Ther., 2015, 98(2), 135-144. doi: 10.1002/cpt.148 PMID: 25974754</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Ding, M.M. The role of IL-17 signaling pathway in the occurrence and development of alcohol-related liver cancer. Liver, 2020, 25, 562.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Pan, Y.; Ren, X.; Zhang, Y.; Lv, J.; Zeng, Q.; Zhang, H.; Yu, Z. IL-17A-mediated ERK1/2/p65 signaling pathway is associated with cell apoptosis after non-alcoholic steatohepatitis. IUBMB Life, 2019, 71(3), 302-309. doi: 10.1002/iub.1960 PMID: 30481403</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Harley, I.T.W. Stankiewicz, T.E.; Giles, D.A.; Softic, S.; Flick, L.M.; Cappelletti, M.; Sheridan, R.; Xanthakos, S.A.; Steinbrecher, K.A.; Sartor, R.B.; Kohli, R.; Karp, C.L.; Divanovic, S. IL‐17 signaling accelerates the progression of nonalcoholic fatty liver disease in mice. Hepatology, 2014, 59(5), 1830-1839. doi: 10.1002/hep.26746 PMID: 24115079</mixed-citation></ref></ref-list></back></article>
